logo
logo

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer

May 06, 2025•3 months ago

Contract Type

partnership

SwedenConsultingBiotechnologyHealth Care

Description

TFS HealthScience is deepening its collaboration with Oncomatryx to support a newly initiated Phase Ib clinical trial evaluating OMTX705—an anti-fibroblast activation protein antibody-drug conjugate (FAP-ADC)— in patients with advanced or metastatic pancreatic adenocarcinoma. The promising results from the previous phase I trial laid the foundation for this next phase of development and exemplified the consistent performance, deep therapeutic expertise, and oncology specialization that Oncomatryx values in its continued partnership with TFS.

Company Information

Company

TFS HealthScience

Location

Sweden

About

Scientific and operational experts tailor solutions to meet the needs of your project from regulatory strategy and clinical operations phases I-III to post-authorization and real-world evidence studies. From global end-to-end clinical development to a single service, we create fit-for-purpose FSP outsourcing models that approach your clinical workforce management efficiently and cost-effectively.

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Related People